Parnell Pharmaceuticals Holdings Ltd
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproduc… Read more
Parnell Pharmaceuticals Holdings Ltd (PARNF) - Net Assets
Latest net assets as of September 2019: $0.00 USD
Based on the latest financial reports, Parnell Pharmaceuticals Holdings Ltd (PARNF) has net assets worth $0.00 USD as of September 2019.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($0.00) and total liabilities ($0.00). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $0.00 |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -1556.77% |
| Growth Volatility | 390.64 |
Parnell Pharmaceuticals Holdings Ltd - Net Assets Trend (2011–2021)
This chart illustrates how Parnell Pharmaceuticals Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Parnell Pharmaceuticals Holdings Ltd (2011–2021)
The table below shows the annual net assets of Parnell Pharmaceuticals Holdings Ltd from 2011 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $-34.79 Million | -9.21% |
| 2020-12-31 | $-31.85 Million | -21.46% |
| 2019-12-31 | $-26.23 Million | -41.55% |
| 2018-12-31 | $-18.53 Million | -63.72% |
| 2017-12-31 | $-11.32 Million | -240.34% |
| 2016-12-31 | $8.06 Million | -60.19% |
| 2015-12-31 | $20.25 Million | -19.26% |
| 2014-12-31 | $25.09 Million | +950.46% |
| 2013-12-31 | $2.39 Million | 0.00% |
| 2012-12-31 | $2.39 Million | -63.70% |
| 2011-12-31 | $6.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Parnell Pharmaceuticals Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3415.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $68.01 Million | % |
| Other Comprehensive Income | $-863.74K | % |
| Total Equity | $-34.79 Million | 100.00% |
Parnell Pharmaceuticals Holdings Ltd Competitors by Market Cap
The table below lists competitors of Parnell Pharmaceuticals Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GREAT WORLD CO HLDG
BE:TTQ
|
$743.29 |
|
Mobilityone Ltd
LSE:MBO
|
$743.68 |
|
Quice Food Industries Ltd
KAR:QUICE
|
$743.93 |
|
Sakana SA
WAR:SKN
|
$745.40 |
|
VITAFOAM NIGERIA PLC
XNSA:VITAFOAM
|
$742.61 |
|
BJNS -H- (BJ3.SG)
STU:BJ3
|
$742.58 |
|
United Brands Ltd
KAR:UBDL
|
$741.85 |
|
MING FAI INTERNATIO
BE:36Y
|
$740.54 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Parnell Pharmaceuticals Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from -31,854,813 to -34,788,227, a change of -2,933,414.
- Net loss of 1,419,593 reduced equity.
- Other comprehensive income decreased equity by 6,008,594.
- Other factors increased equity by 4,494,773.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.42 Million | -4.08% |
| Other Comprehensive Income | $-6.01 Million | -17.27% |
| Other Changes | $4.49 Million | +12.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Parnell Pharmaceuticals Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.87 | $0.08 | x |
| 2013-12-31 | $0.29 | $0.08 | x |
| 2014-12-31 | $-2.64 | $0.08 | x |
| 2015-12-31 | $1.52 | $0.08 | x |
| 2016-12-31 | $0.51 | $0.08 | x |
| 2017-12-31 | $-0.62 | $0.08 | x |
| 2018-12-31 | $-1.02 | $0.08 | x |
| 2019-12-31 | $-1.46 | $0.08 | x |
| 2020-12-31 | $-1.72 | $0.08 | x |
| 2021-12-31 | $-1.20 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Parnell Pharmaceuticals Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.16%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-48.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 1.02% | 0.53% | 0.47x | 4.06x | $-590.53K |
| 2013 | -145.65% | -29.62% | 0.37x | 13.22x | $-3.72 Million |
| 2014 | 0.00% | -177.04% | 0.25x | 0.00x | $-15.35 Million |
| 2015 | -67.82% | -69.05% | 0.43x | 2.28x | $-15.76 Million |
| 2016 | -269.00% | -108.65% | 0.42x | 5.90x | $-22.50 Million |
| 2017 | 0.00% | -120.92% | 0.63x | 0.00x | $-22.00 Million |
| 2018 | 0.00% | 0.49% | 0.79x | 0.00x | $1.98 Million |
| 2019 | 0.00% | -24.77% | 0.74x | 0.00x | $-4.56 Million |
| 2020 | 0.00% | -50.20% | 0.74x | 0.00x | $-11.88 Million |
| 2021 | 0.00% | -4.16% | 0.85x | 0.00x | $2.06 Million |
Industry Comparison
This section compares Parnell Pharmaceuticals Holdings Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Parnell Pharmaceuticals Holdings Ltd (PARNF) | $0.00 | 1.02% | N/A | $742.72 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |